How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

865 results for

Acne Vulgaris Management

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris

Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02709902 Recruitment Status : Completed First Posted : March 16, 2016 Last

2016 Clinical Trials

82. An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris

An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02682264 Recruitment Status : Completed First

2016 Clinical Trials

83. Tazarotene Plus Clindamycin vs. Adapalene Plus Clindamycin in the Treatment of Facial Acne Vulgaris

Tazarotene Plus Clindamycin vs. Adapalene Plus Clindamycin in the Treatment of Facial Acne Vulgaris Tazarotene Plus Clindamycin vs. Adapalene Plus Clindamycin in the Treatment of Facial Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Tazarotene Plus Clindamycin vs. Adapalene Plus Clindamycin in the Treatment of Facial Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02721173 Recruitment Status : Completed First Posted : March 29, 2016 Last Update Posted : January 18, 2017

2016 Clinical Trials

84. An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris

An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02720627 Recruitment Status : Completed First Posted : March

2016 Clinical Trials

85. Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02932306 Recruitment Status : Completed First Posted : October 13, 2016 Last Update Posted : January 10, 2018 Sponsor: Valeant

2016 Clinical Trials

86. Efficacy Study in Patients With Acne Vulgaris.

Efficacy Study in Patients With Acne Vulgaris. Efficacy Study in Patients With Acne Vulgaris. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy Study in Patients With Acne Vulgaris. The safety (...) Study Description Go to Brief Summary: Safety and efficacy study in patients with acne vulgaris Condition or disease Intervention/treatment Phase Acne Vulgaris Drug: ADPS topical product Drug: Placebo Control Phase 2 Detailed Description: randomized, double-blind, placebo controlled, parallel-group, multiple-center study to evaluate the efficacy and safety of ADPS in the treatment of acne vulgaris. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial

2016 Clinical Trials

87. Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris

Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02924428 Recruitment Status : Active, not recruiting First Posted

2016 Clinical Trials

88. Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02929719 Recruitment Status : Completed First Posted : October 11, 2016 Last Update Posted : May 4, 2017 Sponsor

2016 Clinical Trials

89. Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris

Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Teledermatology (...) and Modulation of Antibiotic Dose in Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02905851 Recruitment Status : Completed First Posted : September 19, 2016 Last Update Posted : July 2, 2018 Sponsor: University of California, Davis Information provided by (Responsible Party): University

2016 Clinical Trials

90. Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02959970 Recruitment Status : Completed First Posted : November 9, 2016 Last Update Posted

2016 Clinical Trials

91. Efficacy and Safety of CD5024 1% in Acne Vulgaris

Efficacy and Safety of CD5024 1% in Acne Vulgaris Efficacy and Safety of CD5024 1% in Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety of CD5024 1% in Acne Vulgaris (...) , multi-center, randomised, investigator-blinded, vehicle controlled study using intra-individual comparison involving subjects with acne vulgaris on face to evaluate the efficacy of CD5024 1% cream over a 6-week treatment period compared to its vehicle. Condition or disease Intervention/treatment Phase Acne Drug: CD5024 1% cream Drug: CD5024 cream placebo Drug: CD0271/CD1579 gel Drug: CD0271/CD1579 gel placebo Phase 2 Detailed Description: Study drugs application will be performed once daily, 5 days

2016 Clinical Trials

92. A Study to Evaluate Sebacia Microparticles in Patients With Inflammatory Acne Vulgaris

A Study to Evaluate Sebacia Microparticles in Patients With Inflammatory Acne Vulgaris A Study to Evaluate Sebacia Microparticles in Patients With Inflammatory Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. A Study to Evaluate Sebacia Microparticles in Patients With Inflammatory Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02758041 Recruitment Status : Completed First Posted : May 2, 2016 Last Update Posted : September 7, 2017 Sponsor: Sebacia, Inc. Information

2016 Clinical Trials

93. Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study. (Full text)

Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study. A need exists for topical treatments in managing more severe inflammatory acne.The objectives of this study were to evaluate the efficacy and safety of adapalene 0.3 %/benzoyl peroxide 2.5 % (0.3 % A/BPO) topical gel in subjects with moderate and severe inflammatory (...) acne.This was a multicenter, randomized, double-blind, parallel-group study. Randomization was stratified by acne severity (50 % moderate and 50 % severe). Subjects received 0.3 % A/BPO, 0.1 % A/BPO (benchmark), or vehicle (comparator) once daily for 12 weeks. Co-primary efficacy endpoints were success rate at week 12 (the percentage of subjects rated 'clear' or 'almost clear' with at least a 2-grade improvement on Investigator's Global Assessment [IGA]) and change in inflammatory

2016 American journal of clinical dermatology PubMed

94. Medication Causes of Acne Vulgaris

Medication Causes of Acne Vulgaris Medication Causes of Acne Vulgaris Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Medication (...) Causes of Acne Vulgaris Medication Causes of Acne Vulgaris Aka: Medication Causes of Acne Vulgaris , Drug-induced Acne Vulgaris From Related Chapters II. Causes See Adrenocorticotropic Hormone (ACTH) ( ) Iodide s (e.g. ) s with s that have high (e.g. ) (e.g. ) (e.g. , Loestrin) III. References Fitzpatrick (2009) Color Atlas and Synopsis of Clinical Dermatology, 6th ed, McGraw-Hill, New York Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search

2018 FP Notebook

95. Acne Vulgaris Pathophysiology

Acne Vulgaris Pathophysiology Acne Vulgaris Pathophysiology Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Acne Vulgaris (...) Pathophysiology Acne Vulgaris Pathophysiology Aka: Acne Vulgaris Pathophysiology From Related Chapters II. Pathophysiology: Overview Progression (4 step process) Androgen Mediated Production Keratinous Obstruction of sebaceous follicle outlet (Results in formation of comedones) l Colonization of trapped sebum (with Propionibacterium acnes) Inflammatory reaction ( s, s and cysts) Images Lewis (1918) Gray's Anatomy 20th ed (in at or ) III. Pathophysiology: Androgen Mediated Sebum Production composition s esters

2018 FP Notebook

96. Acne Vulgaris

Acne Vulgaris Acne Vulgaris Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Acne Vulgaris Acne Vulgaris Aka: Acne Vulgaris , Acne From (...) Rapidly progressive, severe inflammatory acne Associated findings Bone diathesis Acne conglobata Severe Associated with dissecting scalp Associated with suppurativa Aggressive treatment required faciale Rapidly progressive facial (esp cheeks) May be a variant of Affects adult women VII. Differential Diagnosis See See secondary acne causes above Perioral Dermatitis VIII. Management See (includes ) IX. Resources: Patient Education Information from your Family Doctor: Acne in Teens X. References Habif

2018 FP Notebook

97. Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris

Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Pharmacokinetics (...) of Topical SB204 in Adolescents With Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02801903 Recruitment Status : Completed First Posted : June 16, 2016 Last Update Posted : October 12, 2018 Sponsor: Novan, Inc. Collaborator: WCCT Global Information provided by (Responsible Party): Novan

2016 Clinical Trials

98. Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02938494 Recruitment Status : Completed First Posted : October 19, 2016 Last Update Posted : January 18, 2018 Sponsor: Valeant

2016 Clinical Trials

99. Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris

Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02944461 Recruitment Status : Completed First Posted : October 25, 2016 Results First Posted : March 1, 2019 Last Update Posted : March 15, 2019 Sponsor: Derm

2016 Clinical Trials

100. Decreased peroxisome proliferator-activated receptor γ level and signalling in sebaceous glands of patients with acne vulgaris. (PubMed)

-activated PPARγ signaling in human sebocyte biology, and suggest that modulating PPARγ- expression and thereby signaling might be a promising strategy for the clinical management of acne vulgaris. © 2016 British Association of Dermatologists. (...) Decreased peroxisome proliferator-activated receptor γ level and signalling in sebaceous glands of patients with acne vulgaris. Little is known about the altered lipid metabolism-related transcriptional events occuring in sebaceous glands of patients with acne vulgaris. Peroxisome proliferator-activated receptor (PPAR)γ, a lipid-activated transcription factor, is implicated in differentiation and lipid metabolism of sebocytes. We have observed that PPARγ and its target genes, ADRP (adipose

2016 Clinical & Experimental Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>